Results 91 to 100 of about 6,309 (194)

Emerging therapies in transthyretin amyloidosis – a new wave of hope after years of stagnancy? [PDF]

, 2020
Transthyretin amyloidosis (ATTR) is a rare, yet underdiagnosed disease characterized by progressive impairment of neurologic and cardiac function due to deposition of misfolded transthyretin.
Butler, Javed, Heidecker, Bettina, Müller, Maximilian L.   +2 more
core   +1 more source

Delays in diagnosis and treatment of ATTR cardiac amyloidosis: A real‐world data analysis

ESC Heart Failure
Aims and Background Cardiac amyloidosis leads to functional cardiac impairment and heart failure. Transthyretin amyloid cardiomyopathy (ATTR‐CM) is the most common form.
Julia Vogel, Sophia Jura, Stephan Settelmeier, Florian Buehning, Tobias Lerchner, Alexander Carpinteiro, Tienush Rassaf, Lars Michel   +7 more
doaj   +1 more source

Role of ^99mTc-pyrophosphate myocardial scintigraphy in assessing the efficiency of tafamidis therapy: a case series

Российский кардиологический журнал
Introduction. In recent years, the detection rate of transthyretin amyloid cardiomyopathy has been rapidly increasing. The only drug registered as a pathogenetic therapy in Russia is tafamidis.
A. A. Shoshina, A. A. Ansheles, S. N. Nasonova, I. V. Zhirov, V. B. Sergienko, S. N. Tereshchenko   +5 more
doaj   +1 more source

Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms [PDF]

, 2023
AIM: The value of disease-modifying treatment (such as tafamidis) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and severe heart failure symptoms has been debated.
Elliott, Perry, Garcia-Pavia, Pablo, Gundapaneni, Balarama, Ines, Monica, Sultan, Marla B   +4 more
core  

Clinical and laboratory test in patients with familial amyloid polyneuropathy (TTR-FAP): differences between symptomatic patients and asymptomatic carriers [PDF]

Introducción: La polineuropatía amiloidótica familiar asociada a transtirretina (PAF-TTR) es una enfermedad causada por el depósito el depósito de amiloide en los tejidos, cuya proteína precursora es la transtirretina.
Buades-Reines, Juan, Gállego-Lezaun, Cristina, Raya-Cruz, Manuel, Ripoll-Vera, Tomás, Usón-Martín, Mercedes   +4 more
core   +1 more source

Systemic ATTR-amyloidosis, a Rare Form of Internal Organ Damage

Рациональная фармакотерапия в кардиологии, 2019
The article presents the case report of a rare hereditary form of systemic ATTR-amyloidosis in Russian patient with a discussion of approaches to the diagnosis and treatment of this form, also based on the own experience in the management of such ...
V. V. Rameev, R. P. Myasnikov, P. P. Vinogradov, L. V. Kozlovskaya, S. V. Moiseev, E. I. Fomicheva, S. A. Beregovskaya, E. A. Mershina, S. A. Kostina, L. A. Strizhakov, A. S. Rameeva, P. P. Tao, O. M. Drapkina   +12 more
doaj   +1 more source

Tafamidis and tafamidis meglumine for amyloid cardiomyopathy [PDF]

Australian Prescriber, 2021
openaire   +2 more sources

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy

Cardiology and Therapy
Introduction Transthyretin amyloidosis (ATTR) is a progressive, heterogeneous rare disease manifesting as ATTR polyneuropathy (ATTR-PN), ATTR cardiomyopathy (ATTR-CM), or a mixed phenotype. Tafamidis meglumine (20 mg po qd) is approved in some markets to
Nicholas Streicher, Leslie Amass, Rong Wang, Jennifer M. Stephens, Traci LeMasters, Rutika Raina, Emma Merrill, Farooq H. Sheikh   +7 more
doaj   +1 more source

Outcomes in Cardiac Transthyretin Amyloidosis and Association With New York Heart Association Class: Real‐World Data

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Results from ATTR‐ACT (Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy) indicate that tafamidis prolongs survival and reduces cardiovascular hospitalizations in cardiac transthyretin amyloidosis (ATTR‐CA ...
Maximilian Leo Müller, Ekaterina Latinova, Anna Brand, Isabel Mattig, Sebastian Spethmann, Daniel Messroghli, Katrin Hahn, Ulf Landmesser, Bettina Heidecker   +8 more
doaj   +1 more source

Utilité des tests fonctionnels dans les neuropathies amyloïdes familiales [PDF]

, 2015
I.4 But du travail Un travail de thèse mené par une doctorante en physiopathologie (Irène Calero-Romero, sous la direction du Prof. F. Feihl, CHUV) a permis de recenser une quinzaine de patients souffrant de NAF (neuropathie amyloïde familiale) et d ...
RANDRETSANILO, T.
core